Actively Recruiting
Phase 3 Study Comparing OLZSAM and Olanzapine for Weight Gain in Youth With Schizophrenia or Bipolar I Disorder
Led by Alkermes, Inc. · Updated on 2026-08-14
220
Participants Needed
47
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare changes in body mass index BMI Z-score in children and adolescents diagnosed with schizophrenia or bipolar I disorder. The study evaluates the effects of two treatments a fixed-dose combination of olanzapine and samidorphan OLZSAM versus olanzapine alone. It is a phase 3, randomized, double-blind trial designed to assess weight gain and related clinical outcomes in pediatric patients. Participants are randomly assigned to receive either OLZSAM or olanzapine. The starting dose of olanzapine is 2.5 mgday or 5 mgday, adjusted by the investigator, with a maximum of 20 mgday. Samidorphan is dosed at 5 or 10 mg. The study lasts up to 52 weeks, with primary weight change assessments at 12 weeks. Treatment groups are compared to monitor changes in BMI Z-score and other clinical measures. Throughout the study, participants undergo regular evaluations including BMI measurements, waist circumference, and psychiatric assessments such as the Positive and Negative Syndrome Scale PANSS for schizophrenia and Young Mania Rating Scale YMRS for bipolar I disorder. Safety is closely monitored by tracking adverse events and treatment discontinuation. The study includes outpatient visits with continued follow-up for up to one year to observe long-term effects on weight and psychiatric symptoms.
CONDITIONS
Brief Title
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Research Team
G
Global Clinical Services
G
Global Clinical Services
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here